Trial · NCT02823080
Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
NCT02823080, Phase 2, Phase 3, Unknown, Benha University; results first posted 2017-01-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome. Trials, record NCT02823080. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02823080
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
- NCT number
- NCT02823080
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 48 participants, actual
- Lead sponsor
- Benha University
- Conditions
- Infertility
- Interventions
- Cetrorelix
- First posted
- 2016-07-06
- Last updated
- 2017-03-30
- Results first posted
- 2017-01-31
- Limitations and caveats
- no Limitations and Caveats
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Daily Serum E2 Levels | 8 days | Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily. |
| Primary | Daily Maximal Ovarian Diameter | 8 days | MOD (maximal ovarian diameter in mm) were evaluated daily. |
| Secondary | Daily Numerical Pain Visual Analogue Scale Score | 8 days. | -All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain . |
| Secondary | Daily Hematocrits Value | 0-8 days. | Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%) |
| Secondary | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | 0-8 days | -US detected severity grades of ascites determined at Day -0, Day -3 and Day -8. |
| Secondary | Daily Total Leucocytic Count | 0 -8days. | TLC(x 1ooo cells/ml) |
| Other | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | 0-6 days | -severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Daily Serum E2 Levels | 8 days | picograms/ml | MEAN | |
| PRIMARY | Daily Maximal Ovarian Diameter | 8 days | mm | MEAN | |
| SECONDARY | Daily Numerical Pain Visual Analogue Scale Score | 8 days. | units on a scale | MEAN | |
| SECONDARY | Daily Hematocrits Value | 0-8 days. | percentge | MEAN | |
| SECONDARY | Ultrasound Detected Severity Grades of Ascites From Days 0-8 | 0-8 days | US detected ascitis | NUMBER | |
| SECONDARY | Daily Total Leucocytic Count | 0 -8days. | 1000 cells/ml | MEAN | |
| OTHER_PRE_SPECIFIED | Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy | 0-6 days | GI manifestations | NUMBER |
Source ClinicalTrials.gov
Results by group160
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Daily Serum E2 Levels | Cetrotide | Day-0 | 4761 | Standard Deviation 940 | picograms/ml |
| Daily Serum E2 Levels | no Cetrotide | Day-0 | 5004 | Standard Deviation 792 | picograms/ml |
| Daily Serum E2 Levels | Cetrotide | Day-1 | 3397 | Standard Deviation 1361 | picograms/ml |
| Daily Serum E2 Levels | no Cetrotide | Day-1 | 4212 | Standard Deviation 950 | picograms/ml |
| Daily Serum E2 Levels | Cetrotide | Day-2 | 2772 | Standard Deviation 1456 | picograms/ml |
| Daily Serum E2 Levels | no Cetrotide | Day-2 | 3620 | Standard Deviation 1037 | picograms/ml |
| Daily Serum E2 Levels | Cetrotide | Day-3 | 2067 | Standard Deviation 900 | picograms/ml |
| Daily Serum E2 Levels | no Cetrotide | Day-3 | 3592 | Standard Deviation 862 | picograms/ml |
| Daily Serum E2 Levels | Cetrotide | Day-4 | 1452 | Standard Deviation 617 | picograms/ml |
| Daily Serum E2 Levels | no Cetrotide | Day-4 | 2570 | Standard Deviation 914 | picograms/ml |
1 to 10 of 160Source ClinicalTrials.gov
See all 160 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cetrotide | 24 | |
| Overall Study | STARTED | no Cetrotide | 24 | |
| Overall Study | COMPLETED | Cetrotide | 24 | |
| Overall Study | COMPLETED | no Cetrotide | 24 | |
| Overall Study | NOT COMPLETED | Cetrotide | 0 | |
| Overall Study | NOT COMPLETED | no Cetrotide | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cetrotide | 0 | 24 |
| Total, all-cause mortality | no Cetrotide | 0 | 24 |
| Total, other adverse events | Cetrotide | 0 | 24 |
| Total, other adverse events | no Cetrotide | 0 | 24 |
| Total, serious adverse events | Cetrotide | 0 | 24 |
| Total, serious adverse events | no Cetrotide | 0 | 24 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cetrotide vs no Cetrotide: deaths from any cause | Trial comparisons |
| Cetrotide vs no Cetrotide: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02823080
GET https://conductscience.org/api/trials/v1/NCT02823080/results?page=2